Literature DB >> 7742207

Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis.

H W Schnaper1.   

Abstract

In glomerular health and disease, the balance between extracellular matrix (ECM) protein synthesis and degradation determines the amount of matrix that accumulates locally. While cell and whole animal regulation of ECM synthesis has been the subject of ongoing study, attention has become focused on proteases that degrade matrix components only recently. Two major ECM protease systems have been defined. The plasminogen activators (PAs) are serine proteases that have matrix-degrading capability and also activate plasminogen to plasmin. Plasmin not only degrades ECM proteins, but also may activate members of the matrix metalloproteinase (MMP) family which comprise the second major matrix-degrading system. Specific biological antagonists of both the PAs and the MMPs tightly regulate proteolysis by these enzymes. All of these enzymes and inhibitors have been detected in the kidney, and their expression may be altered to facilitate ECM accumulation in conditions associated with matrix expansion, such as glomerulosclerosis. Work is in progress to determine how these systems are regulated in the kidney and to further define their contribution to the sclerotic process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742207     DOI: 10.1007/BF00858986

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  98 in total

1.  Interleukin 6 is an autocrine growth factor for mesangial cells.

Authors:  C Ruef; K Budde; J Lacy; W Northemann; M Baumann; R B Sterzel; D L Coleman
Journal:  Kidney Int       Date:  1990-08       Impact factor: 10.612

Review 2.  Glomerular matrix: synthesis, turnover and role in mesangial expansion.

Authors:  J R Couchman; L A Beavan; K J McCarthy
Journal:  Kidney Int       Date:  1994-02       Impact factor: 10.612

Review 3.  The role of systemic and glomerular hypertension in progressive glomerular injury.

Authors:  J Herrera-Acosta
Journal:  Kidney Int Suppl       Date:  1994-02       Impact factor: 10.545

Review 4.  The role of oxidants in progressive renal injury.

Authors:  K A Nath; M Fischereder; T H Hostetter
Journal:  Kidney Int Suppl       Date:  1994-02       Impact factor: 10.545

5.  Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats.

Authors:  C K Abrass; C V Peterson; G J Raugi
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

6.  Primary structure and cDNA cloning of human fibroblast collagenase inhibitor.

Authors:  D F Carmichael; A Sommer; R C Thompson; D C Anderson; C G Smith; H G Welgus; G P Stricklin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

7.  Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta.

Authors:  C M Overall; J L Wrana; J Sodek
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

8.  The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells.

Authors:  P A Marcotte; I M Kozan; S A Dorwin; J M Ryan
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

9.  ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.

Authors:  W H Baricos; S L Cortez; S S el-Dahr; H W Schnaper
Journal:  Kidney Int       Date:  1995-04       Impact factor: 10.612

10.  Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator.

Authors:  J Keski-Oja; J Lohi; A Tuuttila; K Tryggvason; T Vartio
Journal:  Exp Cell Res       Date:  1992-10       Impact factor: 3.905

View more
  18 in total

Review 1.  Decorin-TGFβ axis in hepatic fibrosis and cirrhosis.

Authors:  Kornélia Baghy; Renato V Iozzo; Ilona Kovalszky
Journal:  J Histochem Cytochem       Date:  2012-01-19       Impact factor: 2.479

2.  Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose.

Authors:  Qing Ma; Li Zhang; Lan Yao; Hai-ping Chen; Bao-en Wang
Journal:  Chin J Integr Med       Date:  2014-03-04       Impact factor: 1.978

3.  Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy.

Authors:  Makiho Sekiuchi; Akihiko Kudo; Kimimasa Nakabayashi; Masami Kanai-Azuma; Yoshihiro Akimoto; Hayato Kawakami; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2012-05-22       Impact factor: 2.801

4.  Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining.

Authors:  Tetsuya Endo; Kimimasa Nakabayashi; Makiho Sekiuchi; Tadahide Kuroda; Akinori Soejima; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

5.  Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation.

Authors:  Jehyun Park; Ji Yeon Seo; Hunjoo Ha
Journal:  Korean J Physiol Pharmacol       Date:  2010-12-31       Impact factor: 2.016

6.  Production and degradation of extracellular matrix in reversible glomerular lesions in rat model of habu snake venom-induced glomerulonephritis.

Authors:  Tayo Kawazu; Tomoya Nishino; Yoko Obata; Akira Furusu; Masanobu Miyazaki; Katsushige Abe; Takehiko Koji; Shigeru Kohno
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

7.  Role of aldose reductase in TGF-beta1-induced fibronectin synthesis in human mesangial cells.

Authors:  Yuejuan Zhang; Ping Huang; Tao Jiang; Jingjing Zhao; Nong Zhang
Journal:  Mol Biol Rep       Date:  2009-09-17       Impact factor: 2.316

Review 8.  Progression of glomerular and tubular disease in pediatrics.

Authors:  Robert P Woroniecki; H William Schnaper
Journal:  Semin Nephrol       Date:  2009-07       Impact factor: 5.299

9.  A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Authors:  Yufeng Huang; Masashi Haraguchi; Daniel A Lawrence; Wayne A Border; Ling Yu; Nancy A Noble
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Authors:  Yufeng Huang; Wayne A Border; Ling Yu; Jiandong Zhang; Daniel A Lawrence; Nancy A Noble
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.